OS by sMut status of the entire cohort and favorable risk subset. (A) Median OS was shorter in patients with NPM1-mutated AML with sMut than those without sMut (15.3 months vs 43.7 months; P = .002). (B) When restricted to only patients with favorable risk, median OS was 14.7 months vs not reached (P < .0001).